PSMA theragnostics for metastatic castration resistant prostate cancer

There has been tremendous growth in the development of theragnostics for personalized cancer diagnosis and treatment over the past two decades. In prostate cancer, the new generation of prostate specific membrane antigen (PSMA) small molecular inhibitor-based imaging agents achieve extraordinary tum...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Hong, Guja, Kip E., Iagaru, Andrei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2022
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9163091/
https://www.ncbi.nlm.nih.gov/pubmed/35659674
http://dx.doi.org/10.1016/j.tranon.2022.101438

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9163091/
https://www.ncbi.nlm.nih.gov/pubmed/35659674
http://dx.doi.org/10.1016/j.tranon.2022.101438

Ejemplares similares